Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted a loss for its first quarter on Monday. Pliant Therapeutics posted a quarterly loss of 78 cents per share, versus market expectations for a loss of 77 cents per share, according to data from Benzinga Pro. Research and development expenses rose to $37.1 million from $29.3 million for the year-ago quarter, while general and administrative expenses increased to $15.2 million from $14.2 million. “In the first quarter, we made significant progress across our portfolio, highlighted by the positive safety and exploratory efficacy ...